Motion sensor-acquired reachable workspace correlates with patient-reported upper extremity activities of daily living (ADL) function in facioscapulohumeral dystrophy.
Motion sensor-acquired reachable workspace correlates with patient-reported upper extremity activities of daily living (ADL) function in facioscapulohumeral dystrophy.
复制标题
DOI：
10.1002/mus.27123
复制
发表时间：
2021-02
期刊：
影响因子：
3.4
通讯作者：
Han, Jay J.
中科院分区：
文献类型：
--
作者：
Hatch, Maya N.;Kurillo, Gregorij;Chan, Vicky;Han, Jay J.
本研究探讨面肩肱营养不良（FSHD）患者可达工作空间结果与日常生活活动（ADL）功能之间的相关性和临床意义。21例具有不同疾病严重程度（临床严重程度评分1-4）的FSHD受试者接受了可达工作空间评价，并完成了神经疾病生活质量（NeuroQoL）上肢问卷。进行了斯皮尔曼和受试者操作曲线分析。NeuroQoL评分与总体（ρ = 0.7609; p < 0.01）和上象限RSA（ρ = 0.6969; p < 0.01）之间存在中度相关性。五个特定项目（即穿衬衫，脱衬衫，使用勺子，穿裤子，捡衣服）与总的（ρ = 0.8397; p < 0.01）和肩膀以上的RSA（ρ = 0.8082; p < 0.01）表现出更高的相关性。0.70的总RSA袖带关闭值将实现100%的灵敏度和94%的特异性（AUC = 0.975）。可达工作空间值确定个人在家中进行ADL时有困难。这些信息通过更及时地推荐药物、辅助设备或临床试验入组考虑因素，改善了患者监测和临床决策。
This study examines the correlation, and clinical meaningfulness, between reachable workspace outcome and reported activities of daily living (ADL) function of individuals with facioscapulohumeral dystrophy (FSHD). Twenty-one FSHD subjects with various disease severity (Clinical Severity Scores 1-4) underwent reachable workspace evaluation and completed the Neurological Disorders Quality of Life (NeuroQoL) upper extremity questionnaire. Spearman and receiver operator curve analyses were performed. Moderate correlation was found between NeuroQoL scores and total (ρ = 0.7609; p < 0.01), and upper-quadrants RSAs (ρ = 0.6969; p < 0.01). Five specific items (i.e. shirt on, shirt off, use spoon, pull on pants, pick-up clothes) demonstrated even higher correlations with total (ρ = 0.8397; p < 0.01) and above shoulder RSAs (ρ = 0.8082; p < 0.01). A total RSA cuff-off value of 0.70 would achieve 100% sensitivity and 94% specificity (AUC = 0.975). Reachable workspace values identify when individuals have difficulties performing ADLs at home. This information improves patient monitoring, and clinical decision making by enabling more timely recommendations for medications, assistive devices or considerations for clinical trial enrollments.
登录
查看更多内容
影响因子：
9.9
作者：
Cella, D.;Lai, J-S.;Moy, C.
通讯作者：
Moy, C.
影响因子：
8.6
作者：
Tanji, Haruko;Gruber-Baldini, Ann L.;Shulman, Lisa M.
通讯作者：
Shulman, Lisa M.
DOI：
10.1111/j.1532-5415.1991.tb01616.x
发表时间：
1991-02-01
影响因子：
6.3
作者：
PODSIADLO, D;RICHARDSON, S
通讯作者：
RICHARDSON, S
影响因子：
4.2
作者：
Feld, JA;Rabadi, MH;Jordan, BD
通讯作者：
Jordan, BD
影响因子：
1.6
作者：
Kurillo, Gregorij;Chen, Alic;Han, Jay J.
通讯作者：
Han, Jay J.